



IHC Panel

— A Prognostic Indicator Study —

Panel Code : 10038

Specimen : Tissue

TAT : 4 Days

ER

Estrogen Receptor

PR

Progesteron Receptor

HER-2/Neu

a transmembrane EGF receptor

Ki - 67 (MIB-1)

an indicator of Mitotic Activity

Markers under this Panel

Why US



Reporting is done by the recommended ASCO/CAP Criteria for **HER-2** and with the Allred Score for **ER/PR**



Microphotographs accompany with **each Report**.

Breast cancer, like many other common malignancies are currently classified according to their cells of origin. In the breast duct-acinus system, the most immature and stem-cell like features are seen in the basal/myoepithelial cell and the most mature features are seen in the luminal epithelial cells.

Luminal A	Luminal B	HER2/Neu	Basal - like	
Hormone Receptors +++ HER2 Negative Ki-67 < 14%	Hormone Receptors + HER2 Neg/Pos Ki-67 > 14%	ER/PR Neg HER2 +++ Ki-67 very high	Triple Negative Ki-67 very high	Gene Expression
50%	20%	15%	15%	Frequency
'Good' types	-	'Bad' types	'Bad' types	Histology
Good Response	Good, but less than Luminal A	Poor Response	Nil Response	Endocrine Therapy
Good Response	May/ May not respond	Good Response	Nil Response	Targeted Therapy
Variable response	Variable but greater than A	Good response to Anthracyclines	Cisplatin PARP inhibitors	Chemotherapy
Good	Not as good as Luminal A	Generally poor	Generally poor but not uniformly poor	Prognosis
Not very important	More important	Important	Essential	Role of Molecular Genotype

Get in Touch



A : 12A, CB Road, R S Puram(E), Coimbatore - 641002
 P : 0422 4354242/ 2540525/ 2556628/ 2550673/ 2541316
 E : microlabcbe@microlabindia.com
 W : www.microlabindia.com
 T : 1800 425 1316

Microbiological Laboratory